[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335633-105":59,"doc-detail-335633-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-spliceosome-protein-smd2-as-a-potential-target-for-cancer-therapy","Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy","","Core spliceosome Sm proteins are explored as targets for cancer therapy, with emphasis on SmD2. A pan-cancer analysis across 26 solid tumor types shows SNRPD2, which encodes SmD2, is overexpressed in nearly all cancers, and higher SNRPD2 levels predict poor prognosis in several. SmD2 dependency is tested by silencing SNRPD2 via a short hairpin lentiviral vector in cancer cell lines, cultured melanoma cells, and multiple normal cultures, including cancer-associated fibroblasts. Public viability datasets corroborate SmD2 as a cancer-selective lethal target, linked to intersecting lethal stress in mRNA processing and mitosis, and associated with responses to FDA-approved anti-tumor drugs, especially cell-cycle inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-spliceosome-protein-smd2-as-a-potential-target-for-cancer-therapy/335633/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-spliceosome-protein-smd2-as-a-potential-target-for-cancer-therapy/335633.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What pan-cancer evidence supports SmD2 as a cancer target?","Question",{"text":112,"@type":113},"A pan-cancer analysis of 26 solid tumor types shows SNRPD2 overexpression in almost all cancers, with high SNRPD2 linked to poor prognosis in several cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SmD2 dependency experimentally tested?",{"text":117,"@type":113},"SNRPD2 was silenced using a short hairpin-expressing lentiviral vector in established cancer cell lines, short-term melanoma cultures, and normal cell cultures including cancer-associated fibroblasts.",{"name":119,"@type":110,"acceptedAnswer":120},"What biological processes are associated with vulnerability to SmD2 loss?",{"text":121,"@type":113},"Intersected lethal stress links SmD2 loss with disruptions in multiple essential functions, including mRNA processing such as splicing, coordinated protein production, and mitosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335633,1790218344,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Article  \nEvaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy  \nJing Li 1,2,†, Peiyu Li 1,2,†, Tereza Brachtlova 1,2,3,4, Ida H. van der Meulen-Muileman 1, Henk Dekker 1, Vishal S. Kumar 1, Marieke Fransen 2,4,5, Idris Bahce 4,5,6, Emanuela Felley-Bosco 7  \nand Victor W. van Beusechem 1,2,3,4, *  \nCitation: Li, J.; Li, P.; Brachtlova, T.; van der Meulen-Muileman, I.H.; Dekker, H.; Kumar, V.S.; Fransen, M.; Bahce, I.; Felley-Bosco, E.; van Beusechem, V.W. Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy. Int. J. Mol. Sci. 2024, 25, 13131 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms252313131  \nAcademic Editors: Erik A.C. Wiemer and Alain Couvineau  \nReceived: 9 October 2024  \nRevised: 15 November 2024  \nAccepted: 3 December 2024  \nPublished: 6 December 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands  \n2 Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands  \n3 ORCA Therapeutics BV, Onderwijsboulevard 225, 5223 DE‘s-Hertogenbosch, The Netherlands  \n4 Amsterdam Institute for Infection and Immunity, Cancer Immunology, 1081 HV Amsterdam, The Netherlands  \n5 Amsterdam UMC location Vrije Universiteit Amsterdam, Pulmonary Medicine, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands  \n6 Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands  \n7 Department of Biomedical Sciences, University of Lausanne, Rue du Bugnon 7, CH-1005 Lausanne, Switzerland  \n* [Correspondence: vw.vanbeusechem@amsterdamumc.nl](Correspondence: vw.vanbeusechem@amsterdamumc.nl); Tel.: +31-20-444-2162 † These authors contributed equally to this work.  \nAbstract: The core spliceosome Sm proteins are gaining attention as potential targets for cancer treatment. Here, we evaluate this, with focus on SmD2 . A pan-cancer analysis including 26 solid tumor types revealed that the SmD2-encoding SNRPD2 gene was overexpressed in almost all cancers. In several cancers, high SNRPD2 expression was associated with a poor prognosis. To investigate the vulnerability of human cells to the loss of SmD2 expression, we silenced SNRPD2 using a short hairpin-expressing lentiviral vector in established cancer cell lines; in short-term cultured melanoma cells; and in several normal cell cultures, including cancer-associated fibroblasts cultured from non-small cell lung cancer resections. Additionally, we analyzed publicly available cell viability datasets for the dependency of cancer cell lines to SmD2 expression. Together, these studies clearly established SmD2 as a cancer-selective lethal target. Delving into genes with similar essentiality profiles to SNRPD2, we uncovered the intersected lethal stress between the loss of SmD2 and the loss of gene products participating in not only different mRNA processing steps including mRNA splicing, but also processes for coordinated protein production, as well as mitosis. Furthermore, we could correlate SNRPD2 expression to the responses of cancer cells to several FDA-approved anti-tumor drugs, especially to drugs inhibiting the cell cycle. Overall, our study confirms the anticipated role for targeting SmD2 in cancer treatment and reveals non-canonical SmD2 functions beyond mRNA splicing that could contribute to the dependency of cancer cells to high SNRPD2 expression.  \nKeywords: Sm proteins; pan-cancer analysis; SNRPD2 dependency; drug sensitivity; mitosis  \n1. Introduction  \nRNA splicing, as a fundamental cellular process, play","cbCaitDNzdI8MOx7","https://ap.wps.com/l/cbCaitDNzdI8MOx7","pdf",4407353,"English","# Introduction\n## Spliceosome and RNA splicing in cancer\n## Sm proteins and SmD2 context\n# Abstract","[{\"question\":\"What pan-cancer evidence supports SmD2 as a cancer target?\",\"answer\":\"A pan-cancer analysis of 26 solid tumor types shows SNRPD2 overexpression in almost all cancers, with high SNRPD2 linked to poor prognosis in several cancers.\"},{\"question\":\"How was SmD2 dependency experimentally tested?\",\"answer\":\"SNRPD2 was silenced using a short hairpin-expressing lentiviral vector in established cancer cell lines, short-term melanoma cultures, and normal cell cultures including cancer-associated fibroblasts.\"},{\"question\":\"What biological processes are associated with vulnerability to SmD2 loss?\",\"answer\":\"Intersected lethal stress links SmD2 loss with disruptions in multiple essential functions, including mRNA processing such as splicing, coordinated protein production, and mitosis.\"}]","Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy | PDF",1790011736]